Datar Cancer Genetics

Datar Cancer Genetics (DCG) is a global oncology research and applications company specializing in non-invasive technologies for improved detection, treatment, and management of cancer. The company is a pioneer in liquid biopsy, utilizing proprietary Circulating Tumor Cell (CTC) enrichment and molecular biomarker analysis to provide comprehensive solutions for cancer screening, diagnosis, and therapy guidance. Headquartered in India with state-of-the-art facilities in the UK, USA, and Germany, DCG holds prestigious accreditations including NABL, ISO, CAP, and CLIA. Its portfolio includes revolutionary tests like Trucheck for early-stage screening and Exacta for personalized treatment recommendations, aiming to transform cancer care through data-driven, non-invasive diagnostics.